Please assess the completion status of the following clinical trial:

Trial Title: A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
\*Key Inclusion Criteria\*~All Substudies:~1. At least one measurable target lesions per RECIST 1.1.~2. Eastern Cooperative Group (ECOG) of 0-1.~3. Life expectancy of ≥ 12 weeks~4. Adequate organ and marrow function as defined in the protocol~Substudy 1:~1. Histologically or cytologically confirmed locally advanced, unresectable or metastatic NSCLC, MSS-CRC, or UC.~2. Documented progression from previous therapy~3. NSCLC:~3.a. At least 1 line of systemic therapy in the advanced / metastatic setting 3.b.Must have received anti-PD-1/anti-PD-L1 agent with or without chemotherapy 3.c. Part B and C: Documented no sensitizing EGFR mutations or ALK fusions/rearrangements~4. MSS-CRC: 4.a. At least 2 prior lines of systemic therapy in the advanced / metastatic setting, including specific therapies defined in the protocol~5. UC: 5.a. At least 1 prior line of systemic therapy in the advanced / metastatic setting, including either a platinum-containing regimen and/or an anti-PD-1 or anti-PD-L1 drug 6. Provision of archival tissue or unstained slides 7. Part B: Willing to provide mandatory biposies at screening and on study 8. Part B-CD8+ PET: At least 1 non-liver lesion suitable for PET imaging~\*Key Exclusion Criteria\*~All Substudies:~1. Unresolved toxicities ≥ Grade 2 per CTCAE 5.0 from prior therapy, with some exceptions defined in the protocol~2. Symptomatic CNS metastases or leptomeningeal disease~3. Active or ongoing infections, or uncontrolled intercurrent illness as defined in the protocol~4. Active or prior documented autoimmune or inflammatory disorder~5. Body weight loss of \> 10% within 30 days of screening visit~6. Type 2 diabetes requiring management by metformin, where metformin cannot be switched to another treatment at least 7 days prior to starting study treatment~Substudy 1:~1. Must not have had a toxicity from a checkpoint inhibitor that lead to permanent discontinuation of immunotherapy~2. Participants with brain metastases, unless treated, asymptomatic, stable, and not requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Substudy 1 - Parts A, B, and C (Type: EXPERIMENTAL): * Part A: AZD8853 monotherapy dose escalation~* Part B1 and Part B2: AZD8853 monotherapy safety expansion at dose levels and indications determined to be safe in Part A~* Part C1 and Part C2: AZD8853 monotherapy safety and preliminary efficacy expansion at dose levels and indications determined to be safe in Parts A and B
- Substudy 1 - Parts B1 and B2 with CD8+ PET (Type: EXPERIMENTAL): Sub-set of participants from Parts B1 and B2 will also receive investigational CD8+ T cell targeted radioactive tracer, Zirconium-89 crefmirlimab berdoxam with PET scans

Based on this trial design, predict the completion outcome and termination type (if applicable).